NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival

Medical Hypotheses

Volumn 80, Issue 6, 2013, Pages 728-731

  Baldewpersad Tewarie, Nishita M S ^a   Burgers, Ilsa A V ^a   Dawood, Yousif ^a   den Boon, Hannah C ^a   den Brok, Melina G H E ^a   Klunder, Jet H ^a   Koopmans, Kristijn B ^a   Rademaker, Emma ^a   van den Broek, Hans B ^a   van den Bersselaar, Sil M ^a   Witjes, Julia J ^a   Van Noorden, Cornelis J F ^a   Atai, Nadia A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; GENE MUTATION; GLIOBLASTOMA; HUMAN; IRRADIATION;

CHEMORADIOTHERAPY; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE SILENCING; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MODELS, BIOLOGICAL; MUTATION; NADP; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEINS;

EID: 84877123057     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.02.022     Document Type: Article

References (52)

1. Bondy M.L., Scheurer M.E., Malmer B., et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer 2010, 113:1953-1968.
2. Bleeker F.E., Molenaar R., Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neuro Oncol 2012, 108:11-27.
3. Bleeker F.E., Lamba S., Leenstra S., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7-11.
4. +-dependent IDH activity in glioblastoma. Acta Neuropathol 2010, 119:487-494.
5. Houillier C., Wang X., Kaloshi G., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75:1560-1566.
6. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
7. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: altenations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102:932-941.
8. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2010, 361:1058-1066.
9. Chou H.A., Chen C.Y., Tang J.L., et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010, 115:2749-2754.
10. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
11. Atai N.A., Renkema-Mills N.A., Bosman J., et al. Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem 2011, 59:489-503.
12. Leonardi R., Subramanian C., Jackowski S. Rock C.O. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012, 287:14615-14620.
13. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
14. Koehler A., Van Noorden C.J.F. Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution-induced liver cancer in female flounder. Environ Toxicol Chem 2003, 22:2703-2710.
15. Holmgren A., Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010, 396:120-124.
16. Salvemini F., Franze A., Iervolino A., Filosa S., Salzano S., Ursini M.V. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem 1999, 274:2750-2757.
17. Van Noorden C.J.F., Butcher R.G. A quantitative histochemical study of NADPH-ferrihemoprotein reductase activity. Histochem J 1986, 18:364-370.
18. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007, 96:2181-2196.
19. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009, 100:2235-2241.
20. Aghili M., Zahedi F., Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neuro Oncol 2009, 91:233-236.
21. Chowdhury R., Kheng Yeoh K., Tian Y., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO J 2011, 12:463-469.
22. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
23. Borodovsky A., Seltzer M.J., Riggins G.J. Altered cancer cell metabolism in gliomas with mutant IDH1 and IDH2. Curr Opin Oncol 2012, 24:83-89.
24. Reitman ZJ, Jin GL, Karoly ED, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011;108:3270-5.
25. R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 2012, 22:2339-2355.
26. Williams S.C., Karajannis M.A., Chiriboga L., Golfinos J.G., Von Deimling A., Zagzag D. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol 2011, 121:279-281.
27. Pollard P.J., Ratcliffe P.J. Puzzling patterns of predisposition. Science 2009, 324:192-194.
28. Thompson C.B. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009, 360:813-815.
29. Garber K. Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. J Natl Cancer Inst 2010, 102:926-928.
30. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002-6007.
31. Bjerkvig R., Johansson M., Miletic H., Niclou S.P. Cancer stem cells and angiogenesis. Semin Cancer Biol 2009, 19:279-284.
32. Hughes J.M., Groot A.J., Van der Groep P., et al. Active HIF-1 in the normal human retina. J Histochem Cytochem 2010, 58:247-254.
33. Zhu J., Zuo J., Xu Q., Wang X., Wang Z., Zhou D. Isocitrate dehyrdogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses 2011, 76:602-603.
34. Fu Y., Huang R., Du J., Yang R., An N., Liang A. Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun 2010, 397:127-130.
35. Fu Y., Huang R., Zheng Y., Zhang Z., Liang A. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Biochem Biophys Res Commun 2011, 410:218-223.
36. Mellai M., Monzeglio O., Piazzi A., et al. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neuro Oncol 2012, 107:617-631.
37. Masui K., Cloughesy T.F., Mischel P.S. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012, 38:271-291.
38. Hegi M.E., Liu L., Herman J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
39. Dudek H., Datta S.R., Franke T.F., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
40. Bralten L.B., Kloosterhof N.K., Balvers R., et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 2011, 69:455-463.
41. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
42. Song Tao Q., Lei Y., Si G., et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012, 103:269-273.
43. Mulholland S., Pearson D.M., Hamoudi R.A., et al. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 and IDH2 mutations. Int J Cancer 2012, 131:1104-1113.
44. Van den Bent M.J., Dubbink H.J., Sanson M., et al. MGMT promotor methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC brain tumor group study 26951. J Clin Oncol 2009, 27:5881-5886.
45. Rivera A.L., Pelloski C.E., Gilbert M., et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010, 12:116-121.
46. Sanson M., Marie Y., Paris S., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009, 27:4150-4154.
47. Wick W., Hartmann C., Engel C., et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine and temozolomide. J Clin Oncol 2009, 27:5874-5880.
48. +-specific isocitrate dehydrogenase by oxalacetate and glyoxylate I. Oxalomalate formation and stability, and nature of the enzyme inhibition. Biochem Biophys Acta 1977, 483:24-34.
49. Frederiks W.M., Kümmerlin I.P.E.D., Bosch K.S., Vreeling-Sindelárová H., Jonker A., Van Noorden C.J.F. NADPH production by the pentose phosphate pathway in the zona fasciculata of rat adrenal gland. J Histochem Cytochem 2007, 55:975-980.
50. Piaskowski S., Bienkoswki M., Stoczynska-Fidelus E., et al. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. Br J Cancer 2011, 104:968-970.
51. Artee Luchman H., Stechishin O.D., Ha Dang N., et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012, 14:184-191.
52. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010;70:8981-7.